Vivos Therapeutics, Inc. Overview
Pro stress-test →Vivos Therapeutics is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos' groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate-to-severe OSA in children.
Strategic Profile
Pro stress-test →In Q1 2026, Vivos reported revenue of approximately $5.1 million, up 70% year over year, driven mainly by sleep testing services and its SCN acquisition. On June 10, 2026, Vivos entered into a Collaboration Agreement with South Palm Cardiovascular Associates to form AIM Florida, a management services organization providing administrative, operational, billing, payer-contracting, marketing and other support services to affiliated professional clinical entities that will deliver sleep apnea diagnostic and treatment services.
Competitive Landscape
Pro stress-test →Vivos competes in the obstructive sleep apnea treatment market dominated by established players including ResMed (CPAP/BiPAP devices), Philips Respironics, and conventional surgical approaches. Vivos differentiates through its non-invasive, non-surgical CARE platform targeting dentofacial abnormalities as root cause. The market remains highly fragmented with significant unmet need (80%+ of OSA patients undiagnosed), creating opportunity for innovative treatment modalities.
Industry Context
Vivos Therapeutics, Inc. operates in Sleep apnea diagnostic and treatment devices.
Key facts
Founded: 2016 · Headquarters: Littleton, US · Employees: N/A · Revenue: $5.1M (Q1 2026) · Market cap: N/A